Weight-loss drugs, especially GLP-1 agonists such as Mounjaro and Zepbound, have recently been in the spotlight after Eli Lilly achieved a trillion-dollar valuation. Despite their popularity, new findings reveal that these drugs do not aid Alzheimer's patients, raising concerns about their overall effectiveness. Additionally, there are risks for women who stop taking these medications during pregnancy, as they may experience significant weight gain. Researchers are also worried about postpartum use, where individuals may turn to these drugs to shed pregnancy weight without fully understanding the potential dangers. This situation highlights the pressing need for further research to clarify the benefits and risks associated with GLP-1 agonist drugs.